Is Vertiv Holdings Co (VRT) A Hidden AI Stock to Buy Right Now?
We recently published a list of the 11 Hidden AI Stocks to Buy Right Now. In this article, we are going to take a look at where Vertiv Holdings Co (NYSE:VRT) stands against other hidden AI stocks.
David Grain, Founder & CEO of Grain Management, joined CNBC on May 1 to discuss the AI-driven demand for data centers and tariff uncertainty. The main concerns regarding tariffs are the potential impact on costs, the resilience of supply chains, and the overall effect on business operations and their expansion. He also shared his perspective on why investors are still confident in the broadband and digital infrastructure sector. He characterized broadband as universally essential and emphasised that the demand for faster connectivity has not slowed, which is why the regulatory support for broadband expansion is globally robust. Grain noted that the administration has also met expectations for lighter regulation in the infrastructure sector, which makes it easier to advance projects and close deals. He described the admin's stance as pro-growth and supportive of secure and competitive networks. Grain also observed that infrastructure, especially broadband, is an area where there is bipartisan support, given its positive impact on economic growth at both the state and local levels.
DeepSeek's announcement was also followed by reports that suggested that some companies might be pulling back on data center spending. However, the latest earnings reports appeared to settle at least this debate and confirmed that the investments in this sector were still ongoing. David Grain elaborated on the current trends in data center investments and also stated that the demand for data centers is rising due to the increasing expansion of AI, as it requires vast amounts of computing power. He explained that while the demand here is not slowing, the feasibility of building new data centers is still influenced by the availability of reliable and high-capacity electricity.
Our Methodology
We sifted through financial media reports to compile a list of the top hidden AI stocks with AI-related operations and opportunities. We then selected the 11 stocks that were the most popular among elite hedge funds and that analysts were bullish on. The stocks are ranked in ascending order of the number of hedge funds that have stakes in them, as of Q4 2024.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
China's AI lab unveils RoboBrain 2.0 model to accelerate humanoid robot development
In a move that will further assert China's bid to scale robotics industry, the Beijing Academy of Artificial Intelligence (BAAI)—a not for profit research laboratory—unveiled last week a series of new open-source artificial intelligence (AI) models, dubbed RoboBrain 2.0, that will function as the 'brain' of robots. According to BAAI head Wang Zhongyuan, the use of powerful AI models in China's booming robotics market could accelerate the development and adoption of humanoids, as the sector works to overcome key challenges such as limited model capabilities and a lack of high-quality training data. Wang further explained that BAAI is actively seeking collaboration across the embodied intelligence industry, emphasizing the importance of joint efforts to accelerate progress. He noted that the institute is working with more than 20 leading companies in the sector and is looking to expand its network of partners to drive continued growth. Unveiled as part of China's broader push to advance intelligent machines, RoboBrain 2.0 was described by Wang as the world's most powerful open-source AI model designed to enhance a wide range of robots, including humanoids. Its debut positions BAAI as a potential key player in the evolving sector, the South China Morning Post reported. Furthermore, RoboBrain 2.0 introduces major improvements in spatial intelligence and task planning, delivering a 17% boost in speed and a 74% increase in accuracy compared to the previous version launched just three months earlier. With enhanced spatial intelligence, robots can now perceive distances from surrounding objects more precisely, while advanced task planning enables them to autonomously deconstruct complex activities into manageable steps, significantly improving overall performance. The RoboBrain model is part of the Wujie series, which also includes RoboOS 2.0—a cloud platform for deploying robotics AI models—and Emu3, a multimodal system capable of interpreting and generating text, images, and video. BAAI is one of China's early developers of open-source large language models, the technology behind generative AI chatbots. Several former employees have used their experience at BAAI to start their own AI companies, helping to grow the AI startup community in China. China's push to lead in robotics AI involves multiple players, with BAAI joined by the Beijing Humanoid Robot Innovation Centre, which earlier this year launched Hui Si Kai Wu—a general-purpose embodied AI platform. The center is also known for developing the Tien Kung humanoid robot, which made headlines after completing a half-marathon in Beijing in April. The Chinese institution aims to have its platform become the "Android of humanoid robots," serving as a standard operating system much like Google's Android does in the smartphone industry. Moreover, this year's edition of the BAAI Conference attracted over 100 AI researchers from around the world and more than 200 industry experts, including leaders from major Chinese tech companies such as Baidu, Huawei Technologies, and Tencent Holdings. Additionally, the Chinese academy also announced a strategic partnership with the Hong Kong Investment Corporation to collaborate on talent development, technology advancement, and capital investment aimed at fostering innovation and entrepreneurship in the country's AI sector.
Yahoo
an hour ago
- Yahoo
Klarna CEO warns AI may cause a recession as the technology comes for white-collar jobs
The CEO of payments company Klarna has warned that AI could lead to job cuts and a recession. Sebastian Siemiatkowski said he believed AI would increasingly replace white-collar jobs. Klarna previously said its AI assistant was doing the work of 700 full-time customer service agents. The CEO of the Swedish payments company Klarna says that the rise of artificial intelligence could lead to a recession as the technology replaces white-collar jobs. Speaking on The Times Tech podcast, Sebastian Siemiatkowski said there would be "an implication for white-collar jobs," which he said "usually leads to at least a recession in the short term." "Unfortunately, I don't see how we could avoid that, with what's happening from a technology perspective," he continued. Siemiatkowski, who has long been candid about his belief that AI will come for human jobs, added that AI had played a key role in "efficiency gains" at Klarna and that the firm's workforce had shrunk from about 5,500 to 3,000 people in the last two years as a result. It's not the first time the exec and Klarna have made headlines along these lines. In February 2024, Klarna boasted that its OpenAI-powered AI assistant was doing the work of 700 full-time customer service agents. The company, most famous for its "buy now, pay later" service, was one of the first firms to partner with Sam Altman's company. Later that year, Siemiatkowski told Bloomberg TV that he believed AI was already capable of doing "all of the jobs" that humans do and that Klarna had enacted a hiring freeze since 2023 as it looked to slim down and focus on adopting the technology. However, Siemiatkowski has since dialed back his all-in stance on AI, telling an audience at the firm's Stockholm headquarters in May that his AI-driven customer service cost-cutting efforts had gone too far and that Klarna was planning to now recruit, according to Bloomberg. "From a brand perspective, a company perspective, I just think it's so critical that you are clear to your customer that there will be always a human if you want," he said. In the interview with The Times, Siemiatkowski said he felt that many people in the tech industry, particularly CEOs, tended to "downplay the consequences of AI on jobs, white-collar jobs in particular." "I don't want to be one of them," he said. "I want to be honest, I want to be fair, and I want to tell what I see so that society can start taking preparations." Some of the top leaders in AI, however, have been ringing the alarm lately, too. Anthropic's leadership has been particularly outspoken about the threat AI poses to the human labor market. The company's CEO, Dario Amodei, recently said that AI may eliminate 50% of entry-level white-collar jobs within the next five years. "We, as the producers of this technology, have a duty and an obligation to be honest about what is coming," Amodei said. "I don't think this is on people's radar." Similarly, his colleague, Mike Krieger, Anthropic's chief product officer, said he is hesitant to hire entry-level software engineers over more experienced ones who can also leverage AI tools. The silver lining is that AI also brings the promise of better and more fulfilling work, Krieger said. Humans, he said, should focus on "coming up with the right ideas, doing the right user interaction design, figuring out how to delegate work correctly, and then figuring out how to review things at scale — and that's probably some combination of maybe a comeback of some static analysis or maybe AI-driven analysis tools of what was actually produced." Read the original article on Business Insider Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Hims & Hers Stock Is Soaring Again. But Should You Buy the Stock?
Hims & Hers stock is on the upswing after the company secured a weight-loss drug partnership. Hims & Hers is acquiring its way into Europe and wants to build more personalized drugs for its telehealth customers. Shares have soared, but still have a ton of potential for patient long-term shareholders. 10 stocks we like better than Hims & Hers Health › Many companies have failed to disrupt the complicated U.S. healthcare market. Hims & Hers (NYSE: HIMS) may finally be succeeding in cracking the code. The online telehealth platform focuses on circumventing the insurance market; its business of selling affordable medications directly to individuals is growing like a weed, and expects to generate $6.5 billion in revenue by 2030. It has had a tumultuous start to 2025, as Hims & Hers waged a battle to sell new weight loss medications on its online marketplace. Now, with momentum back on its side, the stock is up 118% year to date and 446% in the last five years. Let's take a deeper look at this company, and see whether you might want to buy Hims & Hers stock for your portfolio now. Hims & Hers' model is simple. It has two separate web platforms -- Hims for men and Hers for women -- that sell medications and deliver to customers' front doors. It began with sexual health, but has moved into dermatology, hair loss, mental health, and now weight loss medications. A key to its success has been avoiding the insurance market with products that don't break the bank. Customers loathe dealing with health insurers in the United States, and sometimes would rather not use insurance at all. Plus, some of these products aren't covered by insurance. This strategy has helped the company close in on over $2 billion in projected revenue in 2025. To keep up this impressive growth, Hims & Hers wants to offer weight loss medications, which have been a blockbuster set of drugs for the pharmaceutical market. For a while the popularity of these drugs, such as Novo Nordisk's Wegovy, left them in short supply; that allowed third parties such as Hims & Hers to produce them as a compounding pharmacy and sell them at much cheaper prices. This ended up generating $200 million of Hims & Hers' $1.4 billion in 2024 revenue. But with the shortage of Wegovy over and the compounding pharmacy exception ended, the company's weight-loss business was at a major turning point. Luckily, at the end of April Hims & Hers announced a partnership with Novo Nordisk that seems to resolve this issue: It gives Hims & Hers the ability to sell Wegovy directly on its platform. Hims & Hers is not an exclusive supplier of the drug -- or any drugs on its marketplaces, to be fair -- but it hopes to use its subscription business model, marketing expertise, and simplified user proposition to drive sales for Novo Nordisk in the huge obesity-care market. Besides weight loss drugs, Hims & Hers has more ambitions to reach its goal of $6.5 billion in revenue by 2030. Just recently, the company announced its intent to acquire European competitor Zava so it could expand its telehealth service to Europe. The acquisition will add a platform with 1.3 million active customers in the U.K., Germany, France, and Ireland. It makes sense that Hims & Hers can supercharge growth for the platform with its plethora of medications offered to customers, keen marketing skills, and subscription-based selling model. Over the long run, Hims & Hers aims to make healthcare for its customers more personalized. This includes unique drug combinations, its own outsourcing facility, and at-home testing capabilities. Details remain sparse, but the vision is clear: disrupting more and more of the trillions of dollars spent on healthcare by building a business that people actually enjoy interacting with. This is why 2.4 million active customers use Hims & Hers today. A revenue goal of $6.5 billion seems well within reach by 2030. Hims & Hers is only at 2.4 million active customers, and there are tens of millions of people in the United States alone who could start using or switch to one of its telehealth platforms. Add on the Zava acquisition in Europe, and the runway for growth gets even larger. The company has an impressive gross profit margin of 77%, which should lead to high levels of profitability at scale. On $6.5 billion in future revenue, it could very well post a net profit margin of over 20%, and achieve $1.5 billion in bottom-line profits and free cash flow. A 20% profit margin is easily achievable because of its high gross margins and the fact it currently spends 40% of revenue on marketing today, a figure that has come down over time and should come down even more as Hims & Hers keeps scaling. However, Hims & Hers has played fast and loose with laws and regulations in the past. It sold weight loss drugs when the legality of doing so was unclear, and although that dispute seems to have been resolved, management could easily start playing with fire again and burn its reputation as a trusted provider of medications. Otherwise, this looks like a fantastic growth stock that just doubled its addressable market with the Zava acquisition. Today, Hims & Hers has a market cap of $12.3 billion. You might think it's overvalued because of the stock's recent run-up in price, but the numbers show that patient investors could be rewarded by holding for the long term. A $12.3 billion market cap is only around 8 times my 2030 earnings estimate of $1.5 billion, which would be a dirt cheap price-to-earnings (P/E) ratio for a fast-growing company compared to the current market cap. Most likely, the stock will be valued at a higher multiple than 8, meaning that the stock will be higher in five years. It doesn't come without risks, but if you're a growth investor, you might love Hims & Hers stock for its long-term potential. Before you buy stock in Hims & Hers Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Hims & Hers Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Brett Schafer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Hims & Hers Stock Is Soaring Again. But Should You Buy the Stock? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
